Market closedNon-fractional
Bio-Rad Laboratories/BIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Bio-Rad Laboratories
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Ticker
BIO
Sector
Healthcare
Trading on
NYSE
Industry
Life Sciences Tools and Services
Headquarters
Hercules, United States
Employees
8,030
Website
www.bio-rad.com
BIO Metrics
BasicAdvanced
$8.9B
Market cap
-
P/E ratio
-$11.15
EPS
0.95
Beta
-
Dividend rate
Price and volume
Market cap
$8.9B
Beta
0.95
Financial strength
Current ratio
6.566
Quick ratio
4.516
Long term debt to equity
13.251
Total debt to equity
13.257
Interest coverage (TTM)
7.20%
Management effectiveness
Return on assets (TTM)
1.69%
Return on equity (TTM)
-3.43%
Valuation
Price to revenue (TTM)
3.501
Price to book
0.97
Price to tangible book (TTM)
1.05
Price to free cash flow (TTM)
49.184
Growth
Revenue change (TTM)
-6.25%
Earnings per share change (TTM)
73.10%
3-year revenue growth (CAGR)
-1.19%
3-year earnings per share growth (CAGR)
-56.55%
What the Analysts think about BIO
Analyst Ratings
Majority rating from 6 analysts.
BIO Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$611M
-10.32%
Net income
$384M
9.78%
Profit margin
62.85%
22.42%
BIO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$3.00
$2.33
$3.10
$2.29
-
Expected
$2.68
$2.78
$2.82
$2.15
$1.95
Surprise
11.99%
-16.26%
10.05%
6.73%
-
BIO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bio-Rad Laboratories stock?
Bio-Rad Laboratories (BIO) has a market cap of $8.9B as of July 26, 2024.
What is the P/E ratio for Bio-Rad Laboratories stock?
The price to earnings (P/E) ratio for Bio-Rad Laboratories (BIO) stock is 0 as of July 26, 2024.
Does Bio-Rad Laboratories stock pay dividends?
No, Bio-Rad Laboratories (BIO) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Bio-Rad Laboratories dividend payment date?
Bio-Rad Laboratories (BIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Bio-Rad Laboratories?
Bio-Rad Laboratories (BIO) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Bio-Rad Laboratories stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.